NEU mention in an AFR article today:
https://www.copyright link/wealth/personal-finance/why-picking-asx-biotechs-is-mostly-for-the-crazy-brave-20240401-p5fggy
Excerpt below -
However, one speculative biotech that has thumped its peers and the broader market is Opthea. The biotech is running two large clinical trials in patients to develop a therapy to treat common eye diseases. The stock has swung wildly over the past five years, with the company boasting around $150 million cash on hand as at December 31.Gerard Satur, the chief executive of investment research firm, stockbroker and asset manager MST Financial, says Opthea is among his top picks for success, alongside neuroscience success story Neuren and neurodegenerative researcher Alterity Therapeutics.“You have to be very selective to invest in biotech stocks on the ASX, there are too many stocks we believe do not offer attractive risk-return as an investment,” says Satur.
Neuren Media and Analyst Coverage, page-946
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.96 |
Change
-2.150(9.30%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $22.50 | $22.70 | $20.28 | $24.29M | 1.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 259 | $20.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.98 | 1641 | 2 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.07 |
Change
-2.150 ( 9.39 %) |
||||
| Open | High | Low | Volume | ||
| $22.45 | $22.67 | $20.27 | 399615 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| NEU (ASX) Chart |